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Abstract
Objective: the study aimed to determine the prevalence of and risk factors for inappropriate prescribing (IP) and prescribing
omission (PO) in elderly with mental co-morbidities.
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Participants: one hundred ﬁfty consecutive inpatients with mental co-morbidities hospitalised for acute medical illness
(mean age 80 ± 9, 70% of women) were considered for the study.
Measurements: IP and PO were prospectively indentiﬁed according to STOPP/START criteria at hospital admission.
Results: over 95% were taking ≥1 medication (median = 7) which amounted to 1,137 prescriptions. The prevalence of IP
was 77% and PO was 65%. The most frequent encountered IP concerned drugs adversely aﬀecting fallers (25%) and anti-
aggregants therapy without atherosclerosis (14%). PO concerned antidepressants with moderate/severe depression (20%)
and calcium-vitamin D supplementation (18%). Independent predictors for IP were increased number of concomitant drugs
(odds ratio [OR] 1.54, 95% conﬁdence interval [CI] 1.13–1.89), being cognitively impaired (OR 1.83, 95% CI 1.55–2.24), and
having fallen in the preceding 3 months (OR 2.03, 95% CI 1.52–2.61) or hospitalised in the preceding year (OR 1.09, 95% CI
1.02–1.23). Concerning PO, psychiatric disorder (OR 1.64, 95% CI 1.42–2.01) and increase level of co-morbidities (OR 1.79,
95% CI 1.48–1.99) were identiﬁed. Living in an institutional setting was a predictive maker for both IP (OR 1.45, 95% CI
1.27–1.74) and PO (OR 1.67, 95% CI 1.32–1.91).
Conclusion: IP and PO were highly prevalent raising the need of a greater health literacy concerning geriatric conditions in
non-geriatrician practitioners who care elderly as well as in the community, in hospital and institutional settings for improving
quality and safety in prescribing medication.
Keywords: inappropriate prescription, omission of prescription, STOPP START, health literacy, older adults
Introduction
In the current increasingly fragmented health care systems,
older patients suﬀering from diﬀerent chronic conditions
consume a large range of medicines. Given by one or several
providers applying evidence-based medicine (EBM) without
coordination, it leads to potential adverse drug events
(ADE) [1]. Within this context, special attention must be
given to potentially inappropriate medication (PIM). A pre-
scribing medication is potentially inappropriate if the risk of
ADE outweighs the clinical beneﬁt, particularly when a safer
or more eﬀective alternative therapy is available for the same
condition. The use of a medication that is known to induce
harmful eﬀects through drug–drug or drug–disease interac-
tions is also inappropriate, as is the prescription of a
medication at a too high dose or for excessive duration [2].
Drug-related errors are the most common type of medical
error, occurring at the time of prescribing through to the
monitoring of patients’ responses. The percentage of hos-
pital admissions due to ADE varies from around 4% in
young people to 16% and more among older persons whose
drug vulnerability is linked to changes in pharmacokinetics
and pharmacodynamics and by impairments in health status
[3, 4]. ADE rank between the fourth and the sixth cause of
death in hospitalised patients, concerning mainly patients in
long-term care or institutional settings. Therefore, ADE re-
presents a clinical and economic burden to patients and
society, and in elderly people PIM has therefore become
an important public health issue worldwide [1].
Another and frequently understated aspect of potentially
inappropriate prescribing (IP) in older people is the omission
of indicated medications with proven eﬃcacy in patients
with a signiﬁcant life expectancy [5, 6]. Among the numer-
ous factors inﬂuencing the appropriateness of prescribing,
people with cognitive and psychiatric disorders are often de-
scribed as the higher risk population [1, 3, 5, 7–9]. A recent
prospective multicentre study of 1,176 hospitalised patients
aged over 75 years (510 with depression and 543 with de-
mentia) showed that half of the studied population was
treated with psychotropics; a multivariate analysis proved
that the prescription of psychotropics was signiﬁcantly
linked to dementia (odds ratio [OR] 1.4, 95% conﬁdence
interval [CI] 1.1–1.9) and to depression syndrome (OR 1.7,
95% CI 1.3–2.1) [9]. Conversely and interestingly, Chan et
al. have observed in a university hospital-based geronto-
psychiatry that between admission and discharge, reducing
the mean number of inappropriate prescription according
to the revised Beers' criteria, in demented inpatient, was sig-
niﬁcantly correlated with the improvement in functional
performance [8].
Whether the literature is abundant concerning PIM
among the elderly with cognitive and/or psychiatric disor-
ders, it mainly focuses on psychotropic drugs [7–9].
Currently, at our knowledge, very few studies concern PIMs
of other medications than psychotropic drugs in this popu-
lation. Above all, very rare are studies having focused the
prescribing omission (PO). This lack could be easily ex-
plained by the lack of appropriate assessment tool. While
explicit and implicit criteria for IP in older people have been
developed (the most commonly cited being Beers' criteria
[10–12], the Improved Prescribing in the Elderly Tool
[13], the Medication Appropriateness Index [14] and the
Assessing Care of Vulnerable Elders—ACOVE [15]),
(i) the suitability of these criteria for day-to-day clinical use is
uncertain,
(ii) many of composing criteria are controversial (up to 50% of
the proscribed drugs in the Beers’ criteria are not listed in
European formularies) and
(iii) the criteria do not explicitly refer to specific drugs that are
problematic in older people nor do they capture problems
of under-use of beneficial medicines [16].
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Thus, the recently developed and validated set of explicit
criteria for PIM use in older adults called Screening Tool of
Older Persons' Prescriptions (STOPP)/Screening Tool to
Alert doctors to Right Treatment (START) gives us the op-
portunity for exploring and analysing more fully PIMs
including PO [2, 5]. It is a reliable and comprehensive
screening tool that enables prescribing physician to appraise
an older patient's prescription drugs in the context of his/
her concurrent diagnoses [17]. Therefore, the main objec-
tives of the present study were, in a population of old
patients with cognitive and/or psychiatric co-morbidities
hospitalised for acute medical conditions to geriatric medicine
units, to (i) prospectively determine the prevalence of and risk
factors for potentially IP according to STOPP criteria and (ii)
to determine the prevalence of and risk factors for potentially
PO according to START criteria in the same population.
Materials and methods
Study population
Data were prospectively collected from consecutive acutely ill
older patients admitted for any acute somatic condition within
a year period (1 January to 31 December 2008) to two specia-
lised units of the Department of Rehabilitation and Geriatrics
of Geneva University hospitals (Switzerland). These units are
dedicated to old patients known to present either behavioural
or psychological symptoms related to dementia (18 acute geri-
atric beds, i.e. Unit A) or any co-morbid psychiatric disorders,
mainly depression (eight acute geriatric beds, i.e. Unit B). All
patients were admitted from the community directly or via the
emergency ward. Patients who were transferred from other
medical or surgical wards for comprehensive geriatric assess-
ment or rehabilitation were not considered. The study
protocol has been approved by the local research committee.
IP assessment
For identifying IP, the French adaptation of STOPP/START
criteria was performed at the patient's admission by two
trained physicians (P.O.L. and Y.H.) [2]. STOPP/START cri-
teria are arranged according to the relevant physiological
systems for ease of use by clinicians (cardiovascular system,
central nervous system and psychotropic drugs, gastrointes-
tinal system, respiratory system, musculoskeletal system,
urogenital system and endocrine system). The content validity
of STOPP/START has been established using a Delphi con-
sensus technique in accordance with the EBM [5]. In addition,
STOPP includes speciﬁc criteria pertaining to analgesic drugs,
drugs that adversely aﬀect older people who fall, and duplicate
drug class prescriptions. STOPP comprises 65 indicators for
potentially IP including drug–drug and drug–disease interac-
tions. Each STOPP criterion is accompanied by a concise
explanation as towhy the prescribing practicemay be inappro-
priate in an older person. START assesses the under-use of
medicines for several common conditions simultaneously
and incorporates 22 evidence-based indicators for PO in older
people (when no contraindication to prescription exists).
Complementary data collection
At the time of admission, demographic information (pa-
tient's age, gender, living condition), number of prescribed
medications, speciﬁc diagnoses and cumulative morbidity,
functional status, number of falls in the preceding 3 months
and number of hospital admissions in the preceding year
were recorded by senior residents in Geriatric Medicine.
Moreover, patients' functional abilities were assessed using
Katz's activities of daily living (ADL) scale [18]. Only ﬁve
of the six ADL in the Katz scale were taken into consider-
ation (continence was not included in accordance with the
classical literature recommendations) [19, 20]. A disabled pa-
tient was deﬁned as functionally dependent for at least one
item. The number of co-morbidity for each patient has been
measured using the cumulative co-morbidity Charlson index
(CCI) applicable to pathologies coded in ICD-10 [21]. For
patients with dementia, both aetiology and severity according
to the Clinical Dementia Rating scale were determined [22].
Statistical analysis
Statistical analysis was performed using the SAS, version 9.1
(SAS Institute, Inc., Cary, NC). Descriptive results pertaining
to numerical variables are presented in the form of mean,
standard deviation (SD) and median. For medication pre-
scriptions (total and potentially inappropriate prescriptions),
the interquartile range (IQR) is also presented. For categor-
ical variables, sample sizes and percentages are presented.
Patient characteristics were compared with respect to
whether their medication prescriptions were potentially in-
appropriate or not according to STOPP/START criteria.
The tests used were chosen according to the type of variables
and the sample size under consideration. Categorical out-
comes were tested using chi-square (χ2) or Fisher's exact
tests; Student's t-test or Mann and Whitney's U-test were
used for numerical outcomes. The single factor analysis re-
sults identiﬁed the variables associated with PIM use. The
selection threshold for the useful variables in multivariable
analysis was set at P = 0.20. All the variables thus selected
were introduced into a logistic regression model. The eﬀects
of the other variables were systematically adjusted for age and
gender. This multifactorial analysis was computed using a
backward elimination procedure (exit threshold P = 0.10)
with authorised re-entry. The results of these analyses were
presented as OR and their 95% CI. The level of signiﬁcance
was set at P = 0.05.
Results
The main characteristics of the study population are pre-
sented in Table 1. Of the 150 patients considered, 70%
were women. The mean age was 80.0 ± 9.1 years. One third
of the population lived in an institutional setting prior to
their hospital admission. Most prevalent co-morbidities in
the population studied were vascular diseases (cerebrovascu-
lar disease 31%, ischaemic heart disease 10%); diabetes
mellitus (14%); chronic pulmonary disease (13%); chronic
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Table 1. Characteristics of the study population and description of prescription drugs and potentially inappropriate medi-
cations (PIM) according to STOPP/START criteria
Patients' characteristics Total Unit A Unit B
n = 150 n = 83 n = 67
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age (years)
mean ± SD 80.0 ± 8.1 80.8 ± 6.6 76.2 ± 7.6
median 81 83 76
Female % (n) 69.3 (104) 57.8 (48) 83.6 (56)
Living in institution % (n) 32.0 (48) 33.7 (28) 29.9 (20)
Disabled for at least one ADL 68.7 (103) 85.5 (71) 47.8 (32)
CCI
Mean ± SD 2.4 ± 2.0 2.6 ± 1.9a 2.0 ± 2.1
Median 2 2 1
Cognitive disorder n (%) 60.6 (91) 100.0 (83)b 11.9 (8)
Clinical Dementia Rating (CDR) scale
Mild cognitive impairment (CDR 0.5) 7.7 (7) 8.5 (7) 0.0 (0)
Mild dementia (CDR 1) 28.5 (26) 25.3 (21) 62.5 (5)
Moderate dementia (CDR 2) 34.1 (31) 33.7 (28) 37.5 (3)
Severe dementia (CDR 3) 29.7 (27) 32.5 (27) 0.0 (0)
Cognitive disorder aetiology
Alzheimer's disease 50.6 (46) 48.2 (40) 75.0 (6)
Vascular disease 6.6 (6) 4.8 (4) 25.5 (2)
Mixed dementia 27.5 (25) 30.1 (25) 0.0 (0)
Other 15.3 (14) 16.9 (14) 0.0 (0)
Psychiatric disorders n (%) 60.6 (91) 28.9 (24) 100.0 (67)c
Depression 61.5 (56) 83.4 (20) 52.3 (35)
Anxiety 8.8 (8) 4.1 (1) 10.4 (7)
Personality disorders 17.6 (16) 12.5 (3) 19.4 (13)
Other 12.1 (11) 0.0 (0) 17.9 (12)
Prescription drugs and PIM
Total number of prescription 1,137 614 523
Mean ± SD 7.58 ± 4.1 7.4 ± 3.7 7.8 ± 4.4
Median 7 7 8
IQR 5–10 5–10 4–11
0 medications % (n) 5.3 (8) 6.0 (5) 4.5 (3)
1–5 medications % (n) 27.3 (41) 26.5 (22) 28.3 (19)
6–9 medications % (n) 40.0 (60) 42.2 (35) 37.3 (25)
≥10 medications % (n) 27.3 (41) 25.3 (21) 29.9 (20)
Potentially inappropriate medication
According to STOPP criteria % (n) 77.3 (116) 77.1 (64) 77.6 (52)
Mean ± SD 1.8 ± 1.7 1.8 ± 1.7 2.2 ± 1.9
Median 1 1 2
IQR 1–2 1–2 1–3
0 PIM % (n) 22.7 (34) 22.9 (19) 22.4 (15)
1–2 PIM % (n) 48.7 (73) 54.2 (45) 41.8 (28)
3–5 PIM % (n) 24.0 (36) 21.7 (18) 26.9 (18)
≥6 PIM % (n) 4.6 (7) 1.2 (1) 8.9 (6)
According to START criteria % (n) 64.7 (97) 63.9 (53) 65.7 (44)
Mean ± SD 1.3 ± 1.3 1.1 ± 1.1 1.4 ± 1.5
Median 1 1 1
IQR 0–2 0–2 0–2
0 PIM % (n) 35.3 (53) 36.1 (30) 34.3 (23)
1–2 PIM % (n) 50.6 (76) 51.8 (43) 49.2 (33)
3–5 PIM % (n) 12.6 (19) 12.0 (10) 13.4 (9)
≥6 PIM % (n) 1.3 (2) 0.0 (0) 3.0 (2)
Unit A = 18 acute geriatric beds dedicated to patients with behavioural and psychological symptoms related to dementia; Unit B = eight acute geriatric beds
dedicated to patients with co-morbid psychiatric disorders.SD, standard deviation; IQR, interquartile range; ADL, activities of daily living; CCI, Charlson co-mor-
bidity index.
aIndicates a significant difference between Unit A and Unit B means (P < 0.05).
bIndicates a significant difference between Unit A and Unit B percentages (P < 0.05).
cChronic kidney disease = serum creatinine > 150 μmol/l or estimated GFR < 50 ml/min according to Cockcroft and Gault.
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kidney disease (13%), deﬁned as serum creatinine >
150 μmol/l or estimated GFR < 50 ml/min according to
Cockcroft and Gault; and congestive heart failure (12%).
Nearly 70% of the population had been hospitalised at least
once in the previous year, and 60% had experienced one or
more falls in the 3 months before admission. A comparative
analysis between the patients of units A and B has been
computed. Excepted for presence of a cognitive disorder
(Unit A: 100%; Unit B: 12%, P < 0.05), presence of a psy-
chiatric co-morbidity (Unit A: 29%; Unit B: 100%, P < 0.05)
and the co-morbidity index (Unit A: 2.6 ± 1.9; Unit B: 2.0 ±
2.1, P < 0.05), no other signiﬁcant diﬀerences were found
between the two groups of patients.
These 150 analysed patients amounted to 1,137 pre-
scriptions. The description of medication prescriptions
and PIMs according to STOPP/START criteria are pre-
sented in Tables 1 and 2. The prevalence of IP and PO
according to STOPP/START criteria are 77% and 65%,
concerning, respectively, 116 and 97 patients. No other stat-
istical diﬀerence was found between the two groups of
patients according to the unit of hospitalisation. Among the
65 STOPP criteria, 25 were never encountered. They mainly
Table 2. Most frequently encountered inappropriate prescribing (IP) and prescribing omission (PO) according to STOPP/
START criteria
IP according to STOPP criteria % (n) Total
n = 150
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cardiovascular system
Aspirin or clopidogrel with no history of coronary, cerebral or peripheral arterial symptoms or occlusive events 14.0 (21)
Loop diuretic as first-line monotherapy for hypertension 8.0 (12)
Loop diuretic for dependent ankle oedema only, i.e. no clinical signs of heart failure 4.0 (6)
Central nervous system and psychotropic drugs
Long-term neuroleptics (>1 month) in those with parkinsonism 14.6 (7)
Long-term (i.e. >1 month), long acting BZD 6.7 (10)
Long-term (i.e. >1 month) neuroleptics as long-term hypnotics 4.7 (7)
Gastrointestinal system
PPI for peptic ulcer disease at full therapeutic dosage for >8 weeks 14.7 (22)
Musculoskeletal system
Long-term use of NSAID (>3 months) for symptom relief of mild osteoarthritis 3.3 (5)
Urogenital system
Bladder antimuscarinic drugs with dementia 3.3 (5)
Drugs that adversely affect fallers
BZD 26.7 (40)
Neuroleptic drugs 24.7 (37)
Vasodilator drugs with persistent postural hypotension, i.e. recurrent >20 mm Hg drop systolic blood pressure 3.3 (5)
Analgesic drugs
Long-term use of powerful opiates, e.g. morphine or fentanyl as first-line therapy for mild to moderate pain 4.0 (6)
Long-term opiates in those with dementia unless indicated for palliative care or management of moderate/severe chronic pain syndrome 4.0 (6)
Duplicate drug classes
Any regular duplicate drug class prescription, e.g. two concurrent opiates, NSAIDs, SSRIs, loop diuretics, ACE inhibitors 16.0 (24)
PO according to START criteria % (n)
Cardiovascular system
Warfarin the presence of chronic atrial fibrillation 6.7 (10)
Aspirin or clopidogrel with a documented history of atherosclerotic coronary, cerebral or peripheral vascular
disease in patients with sinus rhythm
14.7 (22)
Statin with a documented history of coronary, cerebral or peripheral vascular disease, where the patient's
functional status remains independent for ADLs and life expectancy is >5 years
8.0 (12)
ACE inhibitor with chronic heart failure 3.3 (5)
Respiratory system
Regular inhaled β2-agonist or anticholinergic agent for mild to moderate asthma or COPD 8.0 (12)
Regular inhaled corticosteroid for moderate/severe asthma or COPD, where predictive FEV1 < 50% 4.0 (6)
Central nervous system
Antidepressant drug with moderate to severe depressive symptoms lasting ≥ 3 months 20.0 (30)
Gastrointestinal system
Fibre supplement with chronic symptomatic diverticular disease with constipation 9.3 (14)
Musculoskeletal system
Calcium and vitamin D supplement in patients with known osteoporosis (previous fragility fracture, acquired dorsal kyphosis) 18.0 (27)
Endocrine system
Metformin with type 2 DM ± metabolic syndrome 8.0 (12)
Statin therapy in DM if coexisting one major cardiovascular risk factor present 8.0 (12)
BZD, benzodiazepine; PPI, proton pump inhibitor; NSAID, non-steroidal anti-inflammatory drug; SSRI, serotonin selective re-uptake inhibitor; ACE, angiotensin-
converting enzyme; ADL, activities of daily living; COPD, chronic obstructive pulmonary disease; FEV, forced expiratory volume; DM, diabetes mellitus.
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concerned (i) the central nervous system and psychotropic
drugs section (six items): ﬁve concerning tricyclic antide-
pressants and one phenothiazines in patients with epilepsy;
(ii) the cardiovascular system section (ﬁve items): digoxin
at a long-term dose > 125 μg/day with impaired renal
function, non-cardioselective β-blockers with chronic ob-
structive pulmonary disease, diltiazem or verapamil with
NYHA class III or IV heart failure, dipyridamole as
monotherapy for cardiovascular secondary prevention
and aspirin to treat dizziness not clearly attributable to
cerebrovascular disease; and (iii) the musculoskeletal sys-
tem section (ﬁve items): essentially in regards to non-
steroidal anti-inﬂammatory drugs. Among the 22 START
criteria, two were not encountered including (i) home con-
tinuation oxygen with documented chronic type 1 or type 2
respiratory failure and (ii) L-DOPA in idiopathic Parkinson's
disease with deﬁnite functional impairment and resultant
disability (Table 1). The most frequently encountered
STOPP and START criteria are detailed in Table 2.
The unifactorial analysis for factors signiﬁcantly asso-
ciated with at least one instance of STOPP and START
inappropriate medication prescribing is presented in Table 3.
According to the selection threshold, all variables with a
P-value ≤ 0.20 were selected to be introduced into the lo-
gistic regression multifactorial model.
The multivariate analysis demonstrates that demographic
data (age and gender) have no predictive value. Independent
predictors of receiving an IP were the increased number of
medications (OR 1.54, 95% CI 1.13–1.89), being cognitive-
ly impaired (OR 1.83, 95% CI 1.55–2.24) whatever the
severity and aetiology, having fallen at least once in the pre-
ceding 3 months (OR 2.03, 95% CI 1.52–2.61) and
hospitalised at least once in the preceding year (OR 1.09,
95% CI 1.02–1.23). Independent predictors of PO according
to START criteria were the presence of a psychiatric disorder
(OR 1.64, 1.42–2.01) and the number of co-morbidity accord
the Charlson co-morbidity index (OR 1.79, 95% CI 1.48–
1.99). Living in an institutional setting appeared as an inde-
pendent predictive maker for both IP and PO according to
STOPP/START criteria (with respectively, OR 1.45, 95% CI
1.27–1.74 and OR 1.67, 95% CI 1.32–1.91).
Discussion
This prospective study, concerning acutely ill patients with
cognitive or psychiatric disorders, demonstrated the high
rate of PIM in this population.
PIM has been deﬁned using STOPP/START criteria
which were recently developed and validated [2, 5, 16, 17],
following the numerous comments and remarks of the ex-
isting and most cited PIM criteria [5]. At our knowledge,
clinical studies which have used this screening tool, which
appears valid, reliable and comprehensive [17], are still rare.
STOPP/START presents itself as (i) a comprehensive and
Table 3. Results of the unifactorial analysis identifying variables associated with potentially inappropriate medication (PIM)
used according to STOPP/START criteria (results given in form of mean ± SD for numerical variables and percentage
calculated and sample sizes for categorical ones—n = 150)
Characteristics PIM-STOPP PIM-START
No Yes Pa No Yes Pa
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Number of medications 4.1 ± 3.5 8.4 ± 3.8 <0.01 7.4 ± 3.3 7.6 ± 4.4 0.9
Age (year) 80.4 ± 9.4 79.9 ± 7.8 0.6 79.9 ± 7.9 80.0 ± 8.3 0.8
Female 73.5 (25) 75.9 (79) 0.6 67.9 (36) 70.1 (68) 0.8
Living in institution 26.5 (9) 33.6 (39) 0.02 18.9 (10) 39.2 (38) <0.01
Disabled for at least one ADL 55.9 (19) 72.4 (84) 0.09 66.0 (34) 70.1 (68) 0.7
Charlson co-morbidity index 2.1 ± 2.1 2.4 ± 2.0 0.4 1.8 ± 1.8 2.7 ± 2.0 <0.01
Cognitive disorder 28.9 (19) 79.1 (72) 0.02 60.4 (32) 60.8 (59) 0.9
Psychiatric disorders 0.2 <0.01
Depression 68.4 (13) 59.7 (43) 53.1 (17) 66.1 (39)
Anxiety 21.0 (4) 5.6 (4) 12.5 (4) 6.8 (4)
Personality disorders 5.3 (1) 20.8 (15) 12.5 (4) 20.3 (4)
Other 5.3 (1) 13. 9 (10) 21.9 (7) 6.8 (4)
Co-morbidity
Ischaemic heart disease 11.8 (4) 9.5 (11) 0.8 7.6 (4) 11.3 (11) 0.6
Congestive cardiac failure 11.8 (4) 12.9 (15) 0.9 7.6 (4) 15.5 (15) 0.2
Cerebrovascular disease 29.4 (10) 31.0 (36) 0.9 20.7 (11) 36.1 (35) 0.06
Diabetes mellitus 11.8 (4) 14.7 (17) 0.8 7.5 (4) 17.5 (17) 0.1
Chronic kidney diseaseb 11.8 (4) 12.9 (15) 0.9 11.3 (6) 13.4 (13) 0.8
Chronic pulmonary disease 14.7 (5) 12.9 (15) 0.8 1.9 (1) 19.6 (19) 0.002
≥1 Fall in the preceding 3 months 41.2 (14) 65.5 (76) 0.02 60.4 (32) 59.8 (58) 0.9
≥1 Hospitalisation in the preceding year 50.0 (17) 75.0 (87) 0.01 66.0 (35) 71.1 (69) 0.6
SD, standard deviation; PIM-STOPP, PIM according to STOPP criteria; PIM-START, PIM according to START criteria; CDR, Clinical Dementia Rating scale.
aP < 0.05 indicates a significant difference between the two groups (PIM yes–PIM no).
bChronic kidney disease = serum creatinine > 150 μmol/l or estimated GFR < 50 ml/min according to Cockcroft and Gault.
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valid list of potentially inappropriate prescriptions for com-
mon conditions in older adults; (ii) as being based on
current clinical evidence; (iii) as reﬂecting the consensus
opinion of a panel of experts in geriatric medicine, clinical
pharmacology, psychiatry of old age, pharmacy and general
practice; and (iv) including commonly encountered errors of
commission (drug–drug and drug–disease interactions) as
well as instances of PO [5]. A recently published inter-rater
reliability study has shown that a median kappa coeﬃcient
between raters was 0.93 for STOPP criteria and 0.85 for
START criteria, tested between multiple physicians across
six European centres [17]. In addition to this suﬃciently
high inter-rater reliability, the average time for deployment
is suﬃciently low (mean (± SD) time 90 ± 35 s) to make
STOPP/START appropriate to clinical practice [5].
Concerning STOPP criteria, the most frequent drugs pre-
scribed inappropriately are obviously benzodiazepines and
antipsychotic drugs [1, 7–9]. However, in this population
of mentally ill patients, medications from cardiovascular,
gastrointestinal, urogenital and musculoskeletal systems have
been also identiﬁed as being inappropriately prescribed as
showed in details in Table 3. In addition, this table also
shows PO of antidepressants, whilst 30% of the study popu-
lation are at need because of the presence of moderate to
severe depressive symptoms lasting more than 3 months.
PIMs by omission also concerned the cardiovascular, respira-
tory, gastrointestinal, musculoskeletal and endocrine
systems. All these data demonstrate the lack of health liter-
acy concerning geriatric conditions in those in charge of
caring for patients presenting acute medical conditions
and medium/long-term mental disorders simultaneously.
The multifactorial analysis reinforces this point. More than
the factors associated with STOPP criteria (i.e. number of
medications: OR 2.54, cognitive disorder: OR 1.83 and
hospitalisation during the preceding year: OR 1.09), the
factors associated with the presence of START criteria
(PO in case of psychiatric disorders and increasing with
the level of co-morbidity (OR 1.8)) reinforce the notion of
lack of health literacy. They give some evidence of the hur-
dles one encounters when managing multiple co-morbidities
in old patients. Health literacy, broadly deﬁned as the ability
of individuals to access and use health information to make
appropriate health decisions and maintain basic health [23],
is increasingly becoming an issue for health promotion [24].
Lack of knowledge can lead the prescriber(s) to either simply
add medications according to existing guidelines for a spe-
ciﬁc disease, disregarding the presence of other drugs (as
proven by the high prevalence of STOPP criteria in the
present study), or to omit treating essential co-morbidities
(similarly with START criteria). These results suggest that
more in-depth training for medical professionals caring for
old adults is imperatively needed. This need is reinforced by
the results obtained in a study conducted by Arora et al.
[25]. Its speciﬁc aims were to adapt the ACOVE [26]
and quality indicators [27] to evaluate processes of hospital
care of 600 patients, for a broad set of medical conditions,
including general medical conditions (e.g. diabetes mellitus
and heart failure) and conditions prevalent in geriatric medi-
cine (e.g. dementia and delirium, pressure ulcers and urinary
incontinence). The results showed substantial variation in
quality-of-care processes across several domains of care
for hospitalised vulnerable elders, with the lowest quality
of care for conditions found in geriatric patients compared
with general medicine patients [25]. Therefore, greater
health literacy can help health care professionals, other than
geriatricians, to better manage mixed chronic conditions by
combining EBM and existing health care systems to improve
both old adult health and their quality of life.
Moreover, living in an institutional setting was associated
with an increased risk of IP and PO according to STOPP
and START with OR 1.45 and OR 1.67, respectively. Mul-
tiple drug use is common among old, frail nursing home
residents who are susceptible to adverse eﬀects and drug–
drug and/or drug–disease interactions. An institutionalised
population-based study (1,987, mean age 83.7 ± 7.7) with
a mean number of drugs given per resident reaching 7.9
(SD 3.6) discovered IP in 35% of surveyed records [28].
Prescribing omissions were not studied, although they un-
doubtedly also adversely aﬀect health and quality of life of
institutionalised residents. Such data reinforce the need of a
mandatory, speciﬁc and specialised training for practitioners
in charge of nursing homes, which is as yet not organised in
many European countries.
Despite providing important and interesting data, this
study has limitations. Firstly, it was not designed to measure
outcomes such as ADE. Previously published Irish data
showed that the use of STOPP criteria to identify potential
inappropriate prescriptions at hospital admission was twice
more eﬃcient in determining ADE than using Beers' criteria
[16]. Clearly, the association between STOPP/START cri-
teria, PIMs and tangible clinical outcomes such as
hospitalisation, morbidity and mortality needs to be further
investigated by a large-scale and multicentre study. In the
present study, the increased number of medications, that is
polypharmacy, has been identiﬁed as a signiﬁcant predictor
of whether a STOPP criterion will be found (OR 2.54).
Though not a new ﬁnding, the presence of polypharmacy
should prompt a thorough medication review for identify-
ing potentially inappropriate prescriptions and related
ADE. The systematic clinical application of STOPP criteria
to any new prescription may be very eﬀective in this re-
gard. Secondly, factors inﬂuencing PO have not been
evaluated. Therefore, nothing is known concerning pa-
tient's therapeutic observance or/and willingness. Nothing
is known concerning speciﬁc reasons leading patients or
practitioners to continue or discontinue certain medications
(i.e. patients not willing to stop certain medication or not
willing to initiate another one; previous ADE experi-
ence…). Thirdly, as this study was performed in older
patients admitted to acute geriatric units and in a popula-
tion with speciﬁc co-morbidities (acute medical event in
cognitively impaired or psychiatric co-morbid patients),
our results cannot be generalised to the entire elderly
population.
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Conclusion
This study clearly demonstrates that PIM as determined by
STOPP/START criteria in a sample of acutely ill hospitalised
patients with mental co-morbidities is highly prevalent. These
results concern not only IP but also PO. With increasing pro-
portions of older patients worldwide, quality and safety of
prescribing have become global health care issues. We believe
that physicians prescribing to polymorbid and polymedicated
old patients will do this safely only if they develop in-depth
knowledge of common geriatric conditions and learn how
to apply clinical pharmacology principles and EBM tools to
their daily practice as well as in the community, in hospital
and institutional settings. Only then the necessary individual-
isation of therapy can be provided for complex geriatric cases,
without undue approximation and oversimpliﬁcation.
Key points
• In the current increasingly fragmented health care sys-
tems, special attention must be given to PIM in older
population suffering from chronic conditions and con-
suming a large range of medicines.
• Whether the literature is abundant concerning PIM
among the elderly with cognitive and/or psychiatric dis-
orders, it mainly focuses on psychotropic drugs and very
rare are studies having focused the PO.
• Using the STOPP-START criteria, the present study de-
monstrates the high prevalence of PIM, including PO,
which concerns a large panel of drugs.
• The identified independent predictors for PIM raise the
need of a greater health literacy concerning geriatric
conditions in non-geriatrician practitioners who care
elderly as well as in the community, in hospital and in-
stitutional setting.
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